================================================================================
IP ATTRIBUTION FRAMEWORK FOR EoE pMHC-II THERAPEUTIC DESIGN
Ruth-Anne Pai, PhD | July 2026
================================================================================

EXECUTIVE SUMMARY

This document outlines potential intellectual property (IP) claims arising from the 
design and development of multivalent nanoparticle-pMHC-II immunotherapies for 
eosinophilic esophagitis. The work was conducted during the Built with Claude: 
Life Sciences Hackathon (June 28–July 5, 2026) by Ruth-Anne Pai, who:

  • Is an individual researcher (EoE patient, PhD immunology)
  • Holds a professional LLC (Pai Advisory, LLC) for consulting work
  • Is employed full-time by CZ Biohub, Inc.
  • Participated in the hackathon as a professional development activity

THREE POTENTIAL CLAIMANTS

  1. RUTH-ANNE PAI (Individual)
  2. PAI ADVISORY, LLC (Author's business entity)
  3. CZ BIOHUB, INC. (Author's employer)

This framework presents options for IP attribution, each with regulatory, 
commercial, and ethical trade-offs. Final determination requires legal counsel 
review (employment agreement, LLC operating agreement, CZ Biohub IP policy).

================================================================================
LEGAL LANDSCAPE: WORK-FOR-HIRE, OWNERSHIP, & EXTERNAL ACTIVITIES
================================================================================

QUESTION 1: Was this "work" conducted as part of Ruth-Anne Pai's employment duties?

CONTEXT:
  • Hackathon is a "professional development activity"
  • Work occurred outside standard work hours (week-long intensive sprint)
  • Work used Claude AI (Anthropic platform), not CZ Biohub computational infrastructure
  • CZ Biohub did not directly fund, sponsor, or assign the project
  • Personal motivation: patient-driven (EoE sufferer seeking therapeutics for self & community)

TYPICAL EMPLOYMENT IP DOCTRINE:
  - Many tech/biotech companies claim all IP generated during employment, regardless 
    of context, under "work-for-hire" or "assigned inventions" clauses
  - Some companies allow "outside work" if it is (a) unrelated to company business, 
    (b) not conducted on company time/resources, and (c) disclosed in writing
  - Hackathons are increasingly recognized as gray zones: professional development 
    (suggesting employer interest) vs. external initiative (suggesting ownership by individual)

RECOMMENDATION: Review CZ Biohub's employee handbook, employment agreement (Section X: 
Intellectual Property), and any hackathon participation disclosures. This will determine 
whether CZ Biohub has a claim.

================================================================================
QUESTION 2: Did the LLC (Pai Advisory, LLC) participate in the work?

CONTEXT:
  • Ruth-Anne Pai owns Pai Advisory, LLC (consulting business)
  • The hackathon work was not performed under LLC consulting contract
  • No LLC client commissioned the work
  • LLC did not provide resources or bear costs
  • Attribution in manuscript: "Citizen Scientist, EoE patient-researcher" (not LLC-affiliated)

ASSESSMENT:
  • If the LLC was merely a vehicle for Ruth-Anne's independent work (not a separate 
    legal entity with distinct rights), it would not claim independent IP ownership
  • If the LLC has a separate operating agreement assigning "all IP to the LLC," then 
    Ruth-Anne would hold IP in the LLC, not individually
  - If the LLC was used to invoice for time or materials, CZ Biohub may view this as 
    external business activity (supporting individual rather than employer claim)

RECOMMENDATION: Review Pai Advisory, LLC operating agreement. Determine whether:
  (a) LLC is a pass-through entity for Ruth-Anne's independent consulting work, OR
  (b) LLC is a separate legal entity with independent IP assignment obligations

If (a): Ruth-Anne holds IP individually; LLC is a tax/business structure, not an IP holder.
If (b): Ruth-Anne holds IP in the LLC (subject to employer review under Q1).

================================================================================
QUESTION 3: What is CZ Biohub's IP policy?

CONTEXT:
  • CZ Biohub is a major biotech research institute (Chan Zuckerberg Initiative subsidiary)
  • Most large biotech companies claim IP generated during employment, even outside work hours
  • However, some institutions (Stanford, MIT, Harvard) allow "outside activity" IP for 
    faculty/researchers if properly disclosed and unrelated to core business

TYPICAL BIOHUB SCENARIO:
  - If Biohub has a "broad assignment" clause (common in biotech), all IP is assigned 
    to the employer
  - If Biohub has a "core business" carve-out, IP outside core business may be 
    retained if disclosed
  - EoE therapeutics may or may not be within Biohub's core mission (depends on 
    institutional focus: synthetic biology, human cell biology, infectious disease, etc.)

RECOMMENDATION: Consult CZ Biohub's employee handbook, IP policy, and legal department. 
Determine whether:
  (a) All employee IP is assigned to Biohub (broad assignment), OR
  (b) Biohub allows outside IP if properly disclosed and unrelated to core business

================================================================================
SCENARIO ANALYSIS: THREE ATTRIBUTION OPTIONS
================================================================================

OPTION 1: INDIVIDUAL OWNERSHIP (Ruth-Anne Pai)
────────────────────────────────────────────────

CLAIM BASIS:
  • Work was conducted outside employment duties (hackathon sprint, not assigned project)
  • Work used external resources (Claude AI, not Biohub infrastructure)
  • Personal motivation (patient-driven, not employer-assigned)
  • Disclosure to employer (if Biohub allows outside activity)

MANUSCRIPT ATTRIBUTION:
  "This work was conducted by Ruth-Anne Pai as an independent research initiative 
   during the Built with Claude Hackathon (June 28–July 5, 2026), outside her employment 
   duties with CZ Biohub, Inc. Intellectual property for the epitope designs, structural 
   validation, nanoparticle architecture, and preclinical roadmap is retained by Ruth-Anne Pai."

COMPETING INTERESTS STATEMENT:
  "Ruth-Anne Pai is the lead author, an EoE patient, and an employee of CZ Biohub, Inc. 
   This work was conducted as an external professional development initiative; intellectual 
   property is retained by the individual author."

PROS:
  ✓ Simplest ownership structure (one entity, one owner)
  ✓ Allows Ruth-Anne to license directly to biotech partners
  ✓ Aligns with patient-researcher ethos (EoE community ownership)
  ✓ Ruth-Anne can retain upside (future royalties, equity stakes)

CONS:
  ✗ Requires explicit permission from CZ Biohub (may be denied)
  ✗ May create legal/contractual exposure with employer
  ✗ Licensing partners may require Biohub non-assertion to proceed
  ✗ If Biohub later claims IP, litigation could block development

REQUIRES:
  1. CZ Biohub written approval (email or formal IP waiver)
  2. No IP claims from Pai Advisory, LLC
  3. Hackathon conflict-of-interest disclosure (if required)

────────────────────────────────────────────────────────────────────────────────

OPTION 2: LLC OWNERSHIP (Pai Advisory, LLC)
──────────────────────────────────────────────

CLAIM BASIS:
  • Pai Advisory, LLC is Ruth-Anne's consulting business
  • LLC provides a legal structure for holding IP and licensing
  • LLC can enter into biotech partnerships without personal liability exposure
  • Potential tax optimization (C-corp vs. pass-through taxation)

MANUSCRIPT ATTRIBUTION:
  "This work was conducted by Ruth-Anne Pai under Pai Advisory, LLC during the Built with 
   Claude Hackathon (June 28–July 5, 2026). Intellectual property for the epitope designs, 
   structural validation, nanoparticle architecture, and preclinical roadmap is held by 
   Pai Advisory, LLC."

COMPETING INTERESTS STATEMENT:
  "Ruth-Anne Pai is the lead author, an EoE patient, an employee of CZ Biohub, Inc., and 
   the owner of Pai Advisory, LLC. This work was conducted through Pai Advisory, LLC as 
   an external professional development initiative; intellectual property is held by the LLC."

PROS:
  ✓ Legal liability protection (LLC shield for founder)
  ✓ Facilitates biotech partnerships (cleaner IP chain)
  ✓ Potential tax optimization for future licensing revenue
  ✓ Allows Ruth-Anne to distinguish LLC work from employment work

CONS:
  ✗ Requires CZ Biohub approval (same as Option 1)
  ✗ Adds legal complexity (LLC operations, IP assignment, governance)
  ✗ Licensing partners may request personal guarantees anyway
  ✗ If Biohub claims IP, litigation against LLC may still surface employer disputes

REQUIRES:
  1. CZ Biohub written approval (email or formal IP waiver)
  2. Pai Advisory, LLC formal IP assignment (document retention by LLC)
  3. Clear separation between LLC work and Biohub employment
  4. Hackathon conflict-of-interest disclosure (if required)

────────────────────────────────────────────────────────────────────────────────

OPTION 3: SHARED OWNERSHIP (Ruth-Anne Pai + CZ Biohub, Inc.)
──────────────────────────────────────────────────────────────

CLAIM BASIS:
  • Hackathon was a professional development activity (employer interest)
  • Ruth-Anne is an employee (employer claim potential)
  • CZ Biohub may assert implied ownership of all employee IP

MANUSCRIPT ATTRIBUTION:
  "This work was conducted by Ruth-Anne Pai with computational support from Claude AI 
   (Anthropic) during the Built with Claude Hackathon (June 28–July 5, 2026). 
   Intellectual property is jointly held by Ruth-Anne Pai and CZ Biohub, Inc."

COMPETING INTERESTS STATEMENT:
  "Ruth-Anne Pai is the lead author, an EoE patient, and an employee of CZ Biohub, Inc., 
   which holds joint intellectual property for the epitope designs, structural validation, 
   nanoparticle architecture, and preclinical roadmap."

PROS:
  ✓ Complies with broad IP assignment policies (likely favorable to Biohub)
  ✓ Reduces legal risk to both parties (joint ownership = shared liability)
  ✓ Biohub can support licensing/development (institutional resources)
  ✓ Ruth-Anne retains attribution & co-ownership (patient-researcher recognition)

CONS:
  ✗ Requires joint decision-making on licensing (slower, more complex negotiations)
  ✗ Biotech partners may prefer single licensor (Ruth-Anne or Biohub alone)
  ✗ Upside is split between individual and institution
  ✗ Future disputes over commercialization rights are more likely with co-ownership

REQUIRES:
  1. CZ Biohub formal agreement to joint ownership (written, signed)
  2. Clear allocation of rights (e.g., Ruth-Anne: licensing decisions; Biohub: IP prosecution)
  3. Biotech licensing agreement drafted with both parties as licensors

================================================================================
REGULATORY & COMMERCIAL IMPLICATIONS
================================================================================

FDA/IND SUBMISSION:

The FDA does not require a single IP owner for IND approval, but:
  • A single "responsible party" (licensor) simplifies clinical development
  • Shared ownership can delay IND milestones if disputes arise
  • Patent prosecution must list all inventors (Ruth-Anne Pai)
  
  RECOMMENDATION: Whichever ownership option is selected, ensure one party is 
  the primary licensor to biotech partners (fastest IND pathway).

BIOTECH LICENSING:

Potential partners (e.g., Calypse Therapeutics, Cour Pharmaceuticals, others in 
EoE space) will typically prefer:
  • Single licensor (individual or institution, not both)
  • Clear IP chain (no encumbrances or claims)
  • Exclusive license options for defined field-of-use

RECOMMENDATION: Decide ownership before approaching biotech partners. Changing 
ownership mid-negotiation will delay deals.

PUBLICATION:

This manuscript is planned for submission to Science (high-impact venue). 
Science's policy on IP:
  • All authors must declare competing interests
  • IP ownership does NOT affect publication decision
  • Declaring IP ownership strengthens integrity (vs. hiding conflicts)

RECOMMENDATION: Include full IP attribution in Competing Interests statement, 
whichever option is selected.

================================================================================
IMMEDIATE ACTION ITEMS
================================================================================

WEEK 1 (This Week):

  [ ] 1. Review CZ Biohub employment agreement, IP policy, and handbook
         Focus: Is all IP assigned to employer? Is "outside activity" allowed?
         Action: Request from HR or legal department if not available

  [ ] 2. Review Pai Advisory, LLC operating agreement
         Focus: Does LLC claim all IP generated by members? Or is it pass-through?
         Action: Consult LLC formation documents or legal counsel

  [ ] 3. Determine Biohub's hackathon conflict-of-interest policy
         Focus: Does participation in external hackathons require disclosure?
         Action: Contact hackathon organizers or Biohub professional development office

WEEKS 2–3:

  [ ] 4. Draft email to CZ Biohub legal/IP department
         Proposed language:
         "I participated in the Built with Claude: Life Sciences Hackathon (external, 
          professional development activity, June 28–July 5, 2026) and developed IP for 
          EoE therapeutic design using external computational resources (Claude AI). 
          I would like to clarify CZ Biohub's claim to this IP and request guidance on 
          attribution. Please advise whether I may retain individual IP ownership with 
          appropriate disclosure, or whether CZ Biohub asserts a claim."

  [ ] 5. If Biohub approves individual or LLC ownership, request written waiver
         Format: Email confirmation is sufficient; formal waiver document preferred

  [ ] 6. Finalize manuscript attribution & competing interests statement
         (Select Option 1, 2, or 3 above; draft specific language for Science submission)

MONTH 1+:

  [ ] 7. Engage employment counsel (if not already done)
         Scope: Review employment agreement, IP assignment clause, negotiate fair terms 
         with Biohub if they assert a claim

  [ ] 8. Decide: Submit to Science with current IP framework, OR defer publication 
         until IP is fully clarified
         (Recommendation: Clarify now; publication can proceed regardless)

================================================================================
PATIENT-RESEARCHER ETHOS & INSTITUTIONAL POLICY
================================================================================

CITIZEN-SCIENCE ARGUMENT FOR INDIVIDUAL OWNERSHIP:

The manuscript emphasizes that this is "citizen science" work by an EoE patient-researcher. 
This framing supports individual (Ruth-Anne) or LLC ownership, on the grounds that:

  • Patient-driven research is distinct from institutional research
  • EoE community benefit is the primary motivation (not profit)
  • Individual ownership preserves patient-researcher agency in future licensing
  • Licensing to biotech should prioritize EoE patient community interests (e.g., 
    equitable pricing, patient advisory boards)

COUNTER-ARGUMENT (Institutional Support):

CZ Biohub may argue that:
  • Biohub's reputation & name enabled the hackathon work (institutional context)
  • Employee participation in professional development is employer-supported
  • Institutional IP assignment is standard for biotech researchers
  • Joint ownership preserves both patient-researcher agency and institutional support

RECOMMENDATION:

Frame the conversation with CZ Biohub around mutual benefit:
  "I want to acknowledge Biohub's role in supporting this work. I also want to ensure 
   that EoE patient-researcher voices remain central to future development. Can we find 
   a structure that honors both institutional contribution and patient-driven mission?"

Potential compromise: Biohub retains background IP (general pMHC-II nanoparticle 
platform methods), Ruth-Anne retains foreground IP (EoE-specific epitopes and preclinical 
roadmap). This is negotiable.

================================================================================
FINAL RECOMMENDATION FOR COUNSEL REVIEW
================================================================================

OPTION 1 (Individual Ownership) is recommended as the primary path, contingent on:

  1. CZ Biohub written approval (likely if work is deemed "outside core business")
  2. Explicit disclosure to Biohub and Science journal
  3. Clear separation of Biohub employment from hackathon work in all documents

RATIONALE:
  • Simplest ownership structure
  • Aligns with patient-researcher ethos
  • Enables Ruth-Anne to lead biotech partnerships directly
  • Accelerates licensing negotiations (single licensor)
  • Preserves EoE community benefit as primary mission

If CZ Biohub denies Option 1, negotiate Option 3 (shared ownership with clear IP 
allocation: Biohub retains platform methods, Ruth-Anne retains EoE-specific designs 
and preclinical roadmap).

================================================================================
APPENDIX: DOCUMENT CHECKLIST FOR LEGAL COUNSEL
================================================================================

Please provide to your employment law counsel:

  [ ] CZ Biohub employee handbook (IP policy section)
  [ ] Ruth-Anne Pai employment agreement (full text, especially IP assignment clause)
  [ ] CZ Biohub hackathon conflict-of-interest policy (if available)
  [ ] Pai Advisory, LLC operating agreement (full text)
  [ ] This manuscript (Science_manuscript_eoe_pmhc_therapeutics.docx)
  [ ] This IP framework (ip_attribution_framework.txt)
  [ ] Claude AI terms of service (if relevant to IP ownership of AI-assisted work)

For counsel's determination:
  1. Does Ruth-Anne have legal right to retain individual ownership?
  2. If not, is negotiated shared ownership possible?
  3. What is the fairest allocation of upside (royalties, equity) given each party's contribution?
  4. What disclosure is required to CZ Biohub, Science journal, biotech partners, and regulatory authorities?

================================================================================
END OF IP ATTRIBUTION FRAMEWORK
================================================================================